- Home
- ERII vs CRVS Comparison
ERII vs CRVS Comparison
Compare ERII & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERII | CRVS |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 740.3M | 634.0M |
| IPO Year | 2008 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ERII | CRVS |
|---|---|---|
| Price | $13.90 | $7.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $16.50 | $13.75 |
| AVG Volume (30 Days) | 450.6K | ★ 1.6M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.56 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $135,191,000.00 | N/A |
| Revenue This Year | $5.93 | N/A |
| Revenue Next Year | $8.97 | N/A |
| P/E Ratio | $38.72 | ★ N/A |
| Revenue Growth | ★ 0.10 | N/A |
| 52 Week Low | $10.86 | $2.54 |
| 52 Week High | $18.32 | $9.60 |
Technical Indicators
Market Signals| Indicator | ERII | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 38.38 |
| Support Level | $13.68 | $7.34 |
| Resistance Level | $14.75 | $8.00 |
| Average True Range (ATR) | 0.34 | 0.52 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 13.41 | 4.42 |
Price Performance
Historical ComparisonAbout ERII Energy Recovery Inc.
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).